XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
 The following table presents the Company's revenues disaggregated by revenue source:
Year Ended December 31,
(In thousands)202220212020
Screening
Medicare Parts B & C$545,458 $438,646 $365,471 
Commercial743,238 569,944 409,671 
Other136,007 53,718 39,925 
Total Screening1,424,703 1,062,308 815,067 
Precision Oncology
Medicare Parts B & C$197,327 $197,394 $165,799 
Commercial177,518 180,177 153,410 
International117,738 109,913 77,484 
Other108,905 74,192 43,800 
Total Precision Oncology601,488 561,676 440,493 
COVID-19 Testing$58,088 $143,103 $235,831 
Total$2,084,279 $1,767,087 $1,491,391 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics, LLC (“PreventionGenetics”) tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype products and therapy selection products.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $20.3 million for the year ended December 31, 2022. The Company recorded a downward adjustment to revenue from a change in transaction price of $11.8 million for the year ended December 31, 2021. The Company recognized revenue from a change in transaction price of $9.6 million for the year ended December 31, 2020.
The Company had deferred revenue of $3.1 million and $1.0 million as of December 31, 2022 and 2021, respectively. Deferred revenue is reported in other current liabilities in the Company’s consolidated balance sheets.
Revenue recognized for the year ended December 31, 2022, which was included in the deferred revenue balance at the beginning of the year, was not significant. Revenue recognized for the year ended December 31, 2021, which was included in the deferred revenue balance at the beginning of the year, was $24.6 million. Of the $24.6 million of revenue recognized for the year ended December 31, 2021, $24.2 million was related to COVID-19 testing.